Study of sensitization effect of hydroxyurea on chemoradiotherapy of human glioma U251 cells
Yang Yali1, Yang Zhihua2, Pan Wenyan2, Lin Minghui3, Zhang Zixin2, Wang Yanyang2, Shang Jun2, Tang Jing2, Bai Zhoulan2, Zhe Hong4
1Clinical Medical College of Ningxia Medical University, Yinchuan 750004, China; 2Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan 750004, China; 3The Fourth People′s Hospital of Ningxia, Yinchuan 750004, China; 4Cancer Institute of Ningxia Medical University, Yinchuan 750004, China
Abstract：Objective To investigate the effect of hydroxyurea (HU) combined with temozolomide (TMZ) and radiotherapy (RT) on the sensitivity of human glioma U251 cells to chemoradiotherapy (CRT). Methods Human glioma U251 cell line was cultured in vitro. CCK8 cell assay was used to detect the proliferation activity of U251 cells treated with different concentrations of HU/TMZ under different conditions. Flow cytometry was utilized to detect apoptosis rate and cell cycle distribution of U251 cells. Transwell chamber assay and scratch test were performed to evaluate the changes of cell invasion and migration. The expression levels of apoptosis proteins were determined by Western blot. Colony formation assay was adopted to detect the cell survival fraction . Results HU concentration at 50μmol/L and below did not affect the proliferation of human glioma U251 cells (P>0.05). Low-dose HU combined with CRT significantly inhibited cell proliferation (P<0.05), invasion (P<0.01) and migration (12h P<0.001,24h P<0.01), and promoted cell apoptosis (P<0.01) compared with the use of CRT alone. Application of 50μmol/L HU combined with RT increased the radiosensitivity of cells (SER=1.49), significantly prolonged the cell cycle of S phase and G2 phase (both P<0.05), considerably up-regulated the expression levels of the apoptosis-associated proteins of Caspase-3 and Bax and significantly down-regulated the expression level of anti-apoptosis protein of Bcl-2(all P<0.001). Conclusions Compared with CRT, HU combined with CRT can further inhibit the proliferation, invasion and migration of human glioma U251 cells, promote cell apoptosis, increase the radiosensitivity and prolong the cell cycle of S and G2 phases, thereby enhancing the sensitivity of human glioma U251 cells to CRT.
Yang Yali,Yang Zhihua,Pan Wenyan et al. Study of sensitization effect of hydroxyurea on chemoradiotherapy of human glioma U251 cells[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 728-734.
[1] Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the united states in 2012-2016[J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100. DOI:10.1093/neuonc/noz150. [2] Carruthers R, Ahmed SU, Strathdee K, et al. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase[J]. Mol Oncol, 2015, 9(1):192-203. DOI:10.1016/j.molonc.2014.08.003. [3] Madaan K, Kaushik D, Verma T. Hydroxyurea:a key player in cancer chemotherapy[J]. Expert Rev Anticancer Ther, 2012, 12(1):19-29. DOI:10.1586/era.11.175. [4] Kyritsis AP, Yung WK, Jaeckle KA, et al. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas[J]. Neurosurgery, 1996, 39(5):921-926. DOI:10.1097/00006123-199611000-00006. [5] Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide:a review of its discovery, chemical properties, pre-clinical development and clinical trials[J]. Cancer Treat Rev, 1997, 23(1):35-61. DOI:10.1016/s0305-7372(97)90019-0. [6] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5):459-466. DOI:10.1016/S1470-2045(09)70025-7. [7] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996. DOI:10.1056/NEJMoa043330. [8] Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I:resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide[J]. Drug Discov Today, 2015, 20(7):899-905. DOI:10.1016/j.drudis.2015.02.011. [9] Bianco J, Bastiancich C, Jankovski A, et al. On glioblastoma and the search for a cure:where do we stand?[J]. Cell Mol Life Sci, 2017, 74(13):2451-2466. DOI:10.1007/s00018-017-2483-3. [10] Koç A, Wheeler LJ, Mathews CK, et al. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools[J]. J Biol Chem, 2004, 279(1):223-230. DOI:10.1074/jbc. M303952200. [11] Yarbro JW. Mechanism of action of hydroxyurea[J]. Semin Oncol, 1992, 19(3 suppl 9):1-10. [12] Dogruel M, Gibbs JE, Thomas SA. Hydroxyurea transport across the blood-brain and blood-cerebrospinal fluid barriers of the guinea-pig[J]. J Neurochem, 2003, 87(1):76-84. DOI:10.1046/j.1471-4159.2003.01968.x. [13] Shen Z, Xu L, Li J, et al. Capilliposide C sensitizes esophageal squamous carcinoma cells to oxaliplatin by inducing apoptosis through the PI3K/Akt/mTOR pathway[J]. Med Sci Monit, 2017, 23:2096-2103. DOI:10.12659/msm.901183. [14] Shroff EH, Snyder C, Chandel NS. Bcl-2 family members regulate anoxia-induced cell death[J]. Antioxid Redox Signal, 2007, 9(9):1405-1409. DOI:10.1089/ars.2007.1731. [15] Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins:regulators of cell death involved in the pathogenesis of cancer and resistance to therapy[J]. J Cell Biochem, 1996, 60(1):23-32. DOI:10.1002/(SICI)1097-4644(19960101)60:1%3C23::AID-JCB5%3E3.0.CO, 2-5. [16] Mirzayans R, Andrais B, Kumar P, et al. The growing complexity of cancer cell response to dna-damaging agents:caspase 3 mediates cell death or survival?[J]. Int J Mol Sci, 2016, 17(5):708. DOI:10.3390/ijms17050708. [17] Linder M, Tschernig T. Vasculogenic mimicry:Possible role of effector caspase-3, caspase-6 and caspase-7[J]. Ann Anat, 2016, 204:114-117. DOI:10.1016/j.aanat.2015.11.007.
2021, Vol. 30 
